DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Barth syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBarth syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for barth syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 2015 systematic review of Barth syndrome management, covering 28 articles published between 2004 and 2015, found that evidence for specific treatments, therapies, and techniques is lacking in both quality and quantity. The review recommended a flexible, multidisciplinary approach to managing symptoms, with a care team that includes the patient, family, caregivers, and medical, rehabilitative, nutritional, psychological, and educational professionals.
Two neonatal cases reported in 2006 presented with acute metabolic decompensation on the third and first day of life. Symptoms included poor sucking, lethargy, hypotonia, hypothermia, and cardiomyopathy. Laboratory findings showed hypoglycaemia, metabolic acidosis, elevated transaminases, hyperlactacidaemia, and mild hyperammonaemia. Molecular analysis identified a c.877G > A mutation (G197R amino acid substitution) in one patient and a new splice donor c.829 + 1G > A genetic lesion in the other.
A 2015 erratum corrected a reference in a paper that had described a possible ameliorated phenotype in Barth syndrome without tetralinoleoyl cardiolipin deficiency. The corrected reference listed seven functional classes of Barth syndrome mutation.
What is still missing are high-quality clinical trials of any specific drug or therapy for Barth syndrome. The systematic review explicitly notes the lack of evidence for specific treatments. No randomised controlled trials, no survival or response rate data for any drug, and no validated patient stratification tools are reported in these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Multidisciplinary Healthcare · 2015 · 33 citations · open access
Successful management of Barth syndrome: a systematic review highlighting the importance of a flexible and multidisciplinary approach
AbstractThis review describes and summarizes the available evidence related to the treatment and management of Barth syndrome. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards were used to identify articles published between December 2004 and January 2015. The Cochrane Population, Intervention, Control, Outcome, Study Design (PICOS) approach was used to guide the article selection and evaluation process. Of the 128 articles screened, 28 articles matched the systematic review inclusion criteria. The results of this review indicate the need for a flexible and multidisciplinary approach to manage the symptoms most commonly associated with Barth syndrome. It is recommended that a comprehensive care team should include individuals with Barth syndrome, their family members and caregivers, as well as medical, rehabilitative, nutritional, psychological, and educational professionals. The evidence for specific treatments, therapies, and techniques for individuals with Barth syndrome is currently lacking in both quality and quantity.
Journal of Inherited Metabolic Disease · 2006 · 25 citations · open access
Barth syndrome presenting with acute metabolic decompensation in the neonatal period
AbstractWe describe two patients affected by Barth syndrome. Their symptoms became manifest on respectively the third and first day of their lives. Clinical presentation included poor sucking, lethargy, hypotonia, hypothermia and cardiomyopathy. Laboratory findings such as hypoglycaemia, metabolic acidosis, elevated transaminases, hyperlactacidaemia and mild hyperammonaemia pointed to an inborn error of energy metabolism with possible mitochondrial involvement. Molecular analysis of the TAZ (G4.5) gene showed the c.877G > A mutation leading to the G197R amino acid substitution in patient 1, and the new splice donor c.829 + 1G > A genetic lesion in patient 2.
Journal of Inherited Metabolic Disease · 2015 · 0 citations · open access
Erratum to: Barth syndrome without tetralinoleoyl cardiolipin deficiency: a possible ameliorated phenotype
AbstractErratum to: J Inherit Metab Dis (2015) 38:279–286 DOI 10.1007/s10545-014-9747-y The original version of this article unfortunately contained a mistake. The reference by Whited is incomplete. The corrected reference is: Whited K, Baile MG, Currier P, Claypool SM (2013) Seven functional classes of Barth syndrome mutation. Human Molecular Genetics 22:483–492.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
